Skip to main content

Table 6 Comparison of baseline EPH-30 domain scores at other points of follow up (baseline versus 6, 12 and 18 month visits). Values are expressed as median (range) with respective p values

From: A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain

 

Baseline

6 m

p

12 m

p

18 m

p

Pain domain

56.8 (0–95.5)

19.3(0–90.9)

<  0.001

11.4 (0–72.7)

<  0.001

9.08(0–56.8)

<  0.001

Control and powerlessness

75 (0–100)

16.7(0–100)

<  0.001

16.7(0–100)

<  0.001

14.3(0–79.2)

<  0.001

Emotional well-being

54.2 (0–100)

18.7(0–95.8)

0.01

25.4(0–75)

<  0.001

20.8 (0–68.3)

<  0.001

Social support

50 (0–93.6)

15.6 (0–39.5)

0.03

12.5(0–93.7)

<  0.001

12.5(0–100)

0.006

Self-image

58.3 (0–100)

22.5(0–100)

0.004

33.3(0–100)

<  0.001

33.3(0–91.7)

0.001

Work domain

45 (0–85)

12.5(0–80)

0.91

0 (0–80)

0.004

0 (0–70)

0.001